

For brokers and producers only

Date: October 14, 2021

2021 Rx Enhancements

Medical Pharmacy Management (MPM)

Effective **December 1, 2021**, the medications listed below covered under the medical benefit will require prior authorization and/or site of care to better manage rising specialty drug costs.

Impacted members will be notified via letter by November 1. Account-level impact will be distributed to CareFirst Account Management to support account notification of member impact by November 1. Providers will be notified in the October issue of BlueLink.

Prior authorization is required to ensure safe and effective use of these high-cost medications. Through prior authorization, site of care criteria is applied to selected medications as an opportunity to help reduce overall health care costs without compromising quality of care. The outpatient hospital setting is generally recognized as one of the costliest options for specialty infusions with costs up to three times higher compared to non-hospital settings.

To view a full list of medications covered under the medical benefit that require prior authorization or subject to site of care, visit the [Specialty Drug List](#). This list is updated monthly.

Prior Authorization Program Additions

Drug Name	Drug Class	Drug Name	Drug Class
Asparlas	Oncology	Margenza	Oncology
Rylaze	Oncology	Nexviazyme	Lysosomal Storage Disorders and Related Disorders
Saphnelo	Systemic Lupus Erythematosus		

Failure to obtain prior authorization for these drugs may result in the denial of the claim payment.

Site of Care Program Additions

Drug Name	Drug Class
Saphnelo	Systemic Lupus Erythematosus
Nexviazyme	Lysosomal Storage Disorders and Related Disorders

Coverage for these medications at an outpatient hospital setting is approved only if medical

necessity criteria are met at the time of prior authorization. Members have the option to receive their infusion at an alternate site including their home, an ambulatory infusion center or a physician's office.

For more information

If you have any questions, please contact your broker account consultant.